JP2021506238A5 - - Google Patents

Download PDF

Info

Publication number
JP2021506238A5
JP2021506238A5 JP2020530513A JP2020530513A JP2021506238A5 JP 2021506238 A5 JP2021506238 A5 JP 2021506238A5 JP 2020530513 A JP2020530513 A JP 2020530513A JP 2020530513 A JP2020530513 A JP 2020530513A JP 2021506238 A5 JP2021506238 A5 JP 2021506238A5
Authority
JP
Japan
Prior art keywords
rnai construct
pnpla3
nucleotide
rnai
nucleotides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020530513A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021506238A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/065275 external-priority patent/WO2019118638A2/en
Publication of JP2021506238A publication Critical patent/JP2021506238A/ja
Publication of JP2021506238A5 publication Critical patent/JP2021506238A5/ja
Priority to JP2023183884A priority Critical patent/JP2024012386A/ja
Priority to JP2025152531A priority patent/JP2025186376A/ja
Pending legal-status Critical Current

Links

JP2020530513A 2017-12-12 2018-12-12 PNPLA3発現を阻害するためのRNAiコンストラクト Pending JP2021506238A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023183884A JP2024012386A (ja) 2017-12-12 2023-10-26 PNPLA3発現を阻害するためのRNAiコンストラクト
JP2025152531A JP2025186376A (ja) 2017-12-12 2025-09-12 PNPLA3発現を阻害するためのRNAiコンストラクト

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762597841P 2017-12-12 2017-12-12
US62/597,841 2017-12-12
PCT/US2018/065275 WO2019118638A2 (en) 2017-12-12 2018-12-12 Rnai constructs for inhibiting pnpla3 expression and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023183884A Division JP2024012386A (ja) 2017-12-12 2023-10-26 PNPLA3発現を阻害するためのRNAiコンストラクト

Publications (2)

Publication Number Publication Date
JP2021506238A JP2021506238A (ja) 2021-02-22
JP2021506238A5 true JP2021506238A5 (https=) 2022-01-11

Family

ID=65139138

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020530513A Pending JP2021506238A (ja) 2017-12-12 2018-12-12 PNPLA3発現を阻害するためのRNAiコンストラクト
JP2023183884A Pending JP2024012386A (ja) 2017-12-12 2023-10-26 PNPLA3発現を阻害するためのRNAiコンストラクト
JP2025152531A Pending JP2025186376A (ja) 2017-12-12 2025-09-12 PNPLA3発現を阻害するためのRNAiコンストラクト

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023183884A Pending JP2024012386A (ja) 2017-12-12 2023-10-26 PNPLA3発現を阻害するためのRNAiコンストラクト
JP2025152531A Pending JP2025186376A (ja) 2017-12-12 2025-09-12 PNPLA3発現を阻害するためのRNAiコンストラクト

Country Status (23)

Country Link
US (2) US20210139912A1 (https=)
EP (1) EP3724337A2 (https=)
JP (3) JP2021506238A (https=)
KR (1) KR20200097299A (https=)
CN (1) CN111699257A (https=)
AR (1) AR113490A1 (https=)
AU (2) AU2018386089A1 (https=)
BR (1) BR112020011686A2 (https=)
CA (1) CA3084133A1 (https=)
CL (2) CL2020001543A1 (https=)
CO (1) CO2020008485A2 (https=)
CR (1) CR20200304A (https=)
EA (1) EA202091437A1 (https=)
IL (1) IL275029A (https=)
JO (1) JOP20200142A1 (https=)
MX (2) MX2020006088A (https=)
PE (1) PE20210633A1 (https=)
PH (1) PH12020550833A1 (https=)
SG (1) SG11202005257UA (https=)
TW (1) TW201938792A (https=)
UY (1) UY38003A (https=)
WO (1) WO2019118638A2 (https=)
ZA (1) ZA202003982B (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016130806A2 (en) 2015-02-13 2016-08-18 Alnylam Pharmaceuticals, Inc. Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
EA201792263A1 (ru) 2015-04-13 2018-08-31 Элнилэм Фармасьютикалз, Инк. КОМПОЗИЦИИ НА ОСНОВЕ iRNA ПРОТИВ АНГИОПОЭТИН-ПОДОБНОГО БЕЛКА 3 (ANGPTL3) И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
US11603532B2 (en) 2017-06-02 2023-03-14 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
US11597927B2 (en) 2017-06-02 2023-03-07 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
IL277889B2 (en) 2018-04-12 2025-01-01 Wave Life Sciences Ltd Oligonucleotide preparations and methods of using them
EP3790596A4 (en) 2018-05-11 2022-04-06 Wave Life Sciences Ltd. OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE
TWI856973B (zh) 2018-09-19 2024-10-01 美商Ionis製藥公司 Pnpla3表現之調節劑
CN113166761B (zh) * 2018-12-10 2025-09-09 美国安进公司 用于抑制pnpla3表达的rnai构建体
EP4045062A1 (en) * 2019-10-14 2022-08-24 Astrazeneca AB Modulators of pnpla3 expression
US20230078200A1 (en) * 2019-12-09 2023-03-16 Amgen Inc. RNAi CONSTRUCTS AND METHODS FOR INHIBITING LPA EXPRESSION
BR112022011412A2 (pt) 2019-12-16 2022-08-30 Alnylam Pharmaceuticals Inc Composições de irna de domínio de fosfolipase semelhante à patatina contendo proteína 3 (pnpla3) e métodos de uso das mesmas
TW202138559A (zh) * 2019-12-16 2021-10-16 美商阿尼拉製藥公司 含類PATATIN磷脂酶結構域3(PNPLA3)iRNA組成物及其使用方法
EP4096396A1 (en) 2020-01-28 2022-12-07 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized pnpla3 locus and methods of use
TW202202153A (zh) * 2020-03-26 2022-01-16 美商艾羅海德製藥公司 用於抑制PNPLA3表現之RNAi劑、其醫藥組成物及使用方法
KR102812602B1 (ko) 2020-08-05 2025-05-28 다이서나 파마수이티컬, 인크. Lpa 발현을 저해하기 위한 조성물 및 방법
US12084662B2 (en) 2021-04-14 2024-09-10 Dicerna Pharmaceuticals, Inc. Compositions and methods for modulating PNPLA3 expression
AU2022339846A1 (en) * 2021-09-01 2024-03-14 Aligos Therapeutics, Inc. Pnpla3-targeting short interfering rna (sirna) molecules and uses thereof
JP2025542119A (ja) * 2022-12-07 2025-12-25 シャンハイ アルゴ バイオファーマシューティカル カンパニー,リミテッド パタチン様ホスホリパーゼドメイン含有3(pnpla3)の発現を阻害するための組成物及び方法
CN117904108A (zh) * 2022-12-12 2024-04-19 北京福元医药股份有限公司 用于抑制pnpla3基因表达的双链核糖核酸及其修饰物、缀合物和用途
WO2024182446A2 (en) * 2023-02-28 2024-09-06 Aligos Therapeutics, Inc. Pnpla3-targeting short interfering rna (sirna) molecules and uses thereof

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US5719262A (en) 1993-11-22 1998-02-17 Buchardt, Deceased; Ole Peptide nucleic acids having amino acid side chains
US5714331A (en) 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
DE69233501T2 (de) 1991-11-22 2006-02-23 Affymetrix, Inc. (n.d.Ges.d.Staates Delaware), Santa Clara Kombinatorische Strategien für die Polymersynthese
US5981505A (en) 1993-01-26 1999-11-09 The Trustees Of The University Of Pennsylvania Compositions and methods for delivery of genetic material
US5837533A (en) 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
US5556752A (en) 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
US5840710A (en) 1994-12-09 1998-11-24 Genzyme Corporation Cationic amphiphiles containing ester or ether-linked lipophilic groups for intracellular delivery of therapeutic molecules
US5981501A (en) 1995-06-07 1999-11-09 Inex Pharmaceuticals Corp. Methods for encapsulating plasmids in lipid bilayers
US7422902B1 (en) 1995-06-07 2008-09-09 The University Of British Columbia Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US5545531A (en) 1995-06-07 1996-08-13 Affymax Technologies N.V. Methods for making a device for concurrently processing multiple biological chip assays
ATE285477T1 (de) 1995-06-07 2005-01-15 Inex Pharmaceutical Corp Herstellung von lipid-nukleinsäure partikeln duch ein hydrophobische lipid-nukleinsäuree komplexe zwischenprodukt und zur verwendung in der gentransfer
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
US6217900B1 (en) 1997-04-30 2001-04-17 American Home Products Corporation Vesicular complexes and methods of making and using the same
DE69834038D1 (de) 1997-07-01 2006-05-18 Isis Pharmaceutical Inc Zusammensetzungen und verfahren zur verabreichung von oligonukleotiden über die speiseröhre
WO2000003683A2 (en) 1998-07-20 2000-01-27 Inex Pharmaceuticals Corporation Liposomal encapsulated nucleic acid-complexes
US7833992B2 (en) 2001-05-18 2010-11-16 Merck Sharpe & Dohme Conjugates and compositions for cellular delivery
US7491805B2 (en) 2001-05-18 2009-02-17 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
US6693187B1 (en) 2000-10-17 2004-02-17 Lievre Cornu Llc Phosphinoamidite carboxlates and analogs thereof in the synthesis of oligonucleotides having reduced internucleotide charge
US20030130186A1 (en) 2001-07-20 2003-07-10 Chandra Vargeese Conjugates and compositions for cellular delivery
US7109165B2 (en) 2001-05-18 2006-09-19 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
DK1620544T3 (en) 2003-04-17 2019-01-14 Alnylam Pharmaceuticals Inc MODIFIED iRNA AGENTS
US7851615B2 (en) 2003-04-17 2010-12-14 Alnylam Pharmaceuticals, Inc. Lipophilic conjugated iRNA agents
US7723509B2 (en) 2003-04-17 2010-05-25 Alnylam Pharmaceuticals IRNA agents with biocleavable tethers
US8017762B2 (en) 2003-04-17 2011-09-13 Alnylam Pharmaceuticals, Inc. Modified iRNA agents
CA2685127C (en) 2007-04-23 2019-01-08 Alnylam Pharmaceuticals, Inc. Glycoconjugates of rna interference agents
WO2009082607A2 (en) 2007-12-04 2009-07-02 Alnylam Pharmaceuticals, Inc. Targeting lipids
US20100056384A1 (en) * 2008-09-04 2010-03-04 Board Of Regents, The University Of Texas System Sequence Variations in PNPLA3 Associated with Hepatic Steatosis
AR090905A1 (es) 2012-05-02 2014-12-17 Merck Sharp & Dohme Conjugados que contienen tetragalnac y peptidos y procedimientos para la administracion de oligonucleotidos, composicion farmaceutica
EP3564374A1 (en) 2013-06-21 2019-11-06 Ionis Pharmaceuticals, Inc. Compositions and methods for modulation of target nucleic acids
WO2016130806A2 (en) * 2015-02-13 2016-08-18 Alnylam Pharmaceuticals, Inc. Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
EP3350328A1 (en) * 2015-09-14 2018-07-25 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting patatin-like phospholipase domain containing 3 (pnpla3) and methods of use thereof
US10036024B2 (en) * 2016-06-03 2018-07-31 Purdue Research Foundation siRNA compositions that specifically downregulate expression of a variant of the PNPLA3 gene and methods of use thereof for treating a chronic liver disease or alcoholic liver disease (ALD)
US11603532B2 (en) * 2017-06-02 2023-03-14 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
US11597927B2 (en) * 2017-06-02 2023-03-07 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
CN113166761B (zh) * 2018-12-10 2025-09-09 美国安进公司 用于抑制pnpla3表达的rnai构建体

Similar Documents

Publication Publication Date Title
JP2021506238A5 (https=)
JP2024105284A5 (https=)
HRP20210612T1 (hr) Postupci i pripravci za specifičnu inhibiciju glikolat oksidaze (hao1) pomoću dvolančane rnk
JP2019141097A5 (https=)
JP2017079776A5 (https=)
HRP20211410T1 (hr) Pripravci i postupci za inhibiciju ekspresije gena lpa
JP2020094063A5 (https=)
JP2009513144A5 (https=)
JP2016513976A5 (https=)
JP2015511821A5 (https=)
JP2016518331A5 (https=)
JP2018110601A5 (https=)
JP2016522817A5 (https=)
JP2014513954A5 (https=)
JP2017070307A5 (https=)
JP2014527401A5 (https=)
IL316808A (en) Modified double-stranded RNA materials and their uses
JP2014518612A5 (https=)
JP2018531037A5 (https=)
JP2018519835A5 (https=)
JP2018507711A5 (https=)
RU2015151202A (ru) Композиции и способы модулирования экспрессии hbv и ttr
MX355408B (es) Inhibidores a base de oligonucleotidos que comprenden un motivo de acido nucleico bloqueado.
JP2019524151A5 (https=)
JP2021505129A5 (https=)